Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 févr. 2022 18h48 HE
|
Yumanity Therapeutics Inc
BOSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739
19 janv. 2022 07h30 HE
|
Yumanity Therapeutics Inc
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity’s Approach to Neurodegenerative Diseases Validated by Two External Collaborations
11 janv. 2022 08h00 HE
|
Yumanity Therapeutics Inc
Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment Michael J. Fox Foundation awards grant to accelerate early proof-of-concept...
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 janv. 2022 16h05 HE
|
Yumanity Therapeutics Inc
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference
04 janv. 2022 08h00 HE
|
Yumanity Therapeutics Inc
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 déc. 2021 18h00 HE
|
Yumanity Therapeutics Inc
BOSTON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences
16 nov. 2021 16h30 HE
|
Yumanity Therapeutics Inc
BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
15 nov. 2021 07h30 HE
|
Yumanity Therapeutics Inc
Announced Successful Phase 1b trial for YTX-7739 in Parkinson’s disease patients; YTX-7739 was well tolerated and demonstrated target engagement and favorable PK/PD and safety profiles Company...
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 nov. 2021 16h05 HE
|
Yumanity Therapeutics Inc
BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson’s Disease; Company Plans to Advance Program to Phase 2
10 nov. 2021 07h00 HE
|
Yumanity Therapeutics Inc
YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson’s disease YTX-7739 found to be generally well tolerated, demonstrating favorable...